Main

processing priority

4

site type

0 (generic, awaiting analysis)

review version

11

html import

20 (imported)

Events

first seen date

2024-02-22 21:09:50

expired found date

-

created at

2024-05-31 18:14:22

updated at

2025-12-25 23:37:53

Domain name statistics

length

13

crc

51461

tld

2211

nm parts

0

nm random digits

0

nm rare letters

0

Connections

is subdomain of id

-

previous id

0

replaced with id

0

related id

-

dns primary id

94587248

dns alternative id

0

lifecycle status

0 (unclassified, or currently active)

Subdomains and pages

deleted subdomains

0

page imported products

0

page imported random

0

page imported parking

0

Error counters

count skipped due to recent timeouts on the same server IP

0

count content received but rejected due to 11-799

0

count dns errors

0

count cert errors

0

count timeouts

0

count http 429

0

count http 404

0

count http 403

0

count http 5xx

0

next operation date

-

Server

server bits

server ip

-

Mainpage statistics

mp import status

20

mp rejected date

-

mp saved date

-

mp size orig

37768

mp size raw text

11105

mp inner links count

0

mp inner links status

20 (imported)

Open Graph

title

ULTOMIRIS (ravulizumab-cwvz) | Official Patient Website

description

ULTOMIRIS treats generalized myasthenia gravis, aHUS, and PNH. Please see Important Safety Information and full Prescribing Information, including Boxed WARNING.

image

site name

author

updated

2025-12-13 03:24:26

raw text

ULTOMIRIS (ravulizumab-cwvz) | Official Patient Website Skip to content Visit Website Home Important Safety Information ULTOMIRIS Indications ULTOMIRIS REMS Full Prescribing Information Medication Guide Healthcare Professionals ULTOMIRIS ®  is the first and only long-acting medication that provides up to 8 weeks of freedom between infusions* Remember to speak with your doctor about your generalized myasthenia gravis, atypical-HUS, or PNH symptoms and how to manage your condition. *Starting 2 weeks after the initial loading dose, maintenance doses are administered once every 8 weeks for adult patients with gMG, atypical-HUS, and PNH and once every 4 or 8 weeks for pediatric patients one month of age or older (depending on body weight) with atypical-HUS and PNH. ULTOMIRIS is a treatment for people diagnosed with: Generalized Myasthenia Gravis ULTOMIRIS is a prescription medicine used to treat adults with a disease called anti-acetylcholine rece...

Text analysis

redirect type

30 (window.location)

block type

0 (no issues)

detected language

1 (English)

category id

Koronawirus (17)

index version

2025110801

spam phrases

0

Text statistics

text nonlatin

0

text cyrillic

0

text characters

8971

text words

1670

text unique words

470

text lines

115

text sentences

81

text paragraphs

28

text words per sentence

20

text matched phrases

5

text matched dictionaries

3

RSS

rss path

rss status

3 (priority 3 already searched, no matches found)

rss found date

-

rss size orig

0

rss items

0

rss spam phrases

0

rss detected language

0 (awaiting analysis)

inbefore feed id

-

inbefore status

0 (new)

Sitemap

sitemap path

sitemap status

1 (priority 1 already searched, no matches found)

sitemap review version

1

sitemap urls count

0

sitemap urls adult

0

sitemap filtered products

0

sitemap filtered videos

0

sitemap found date

-

sitemap process date

2024-06-30 11:17:11

sitemap first import date

-

sitemap last import date

-